These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

711 related items for PubMed ID: 11803184

  • 1. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
    Hacke W.
    Cerebrovasc Dis; 2002; 13 Suppl 1():22-6. PubMed ID: 11803184
    [Abstract] [Full Text] [Related]

  • 2. Evidence with antiplatelet therapy and ADP-receptor antagonists.
    Easton JD.
    Cerebrovasc Dis; 2003; 16 Suppl 1():20-6. PubMed ID: 12698015
    [Abstract] [Full Text] [Related]

  • 3. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data.
    Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ.
    Cerebrovasc Dis; 2004; 17(2-3):253-61. PubMed ID: 14981346
    [Abstract] [Full Text] [Related]

  • 4. Insights from CURE: using clopidogrel on top of standard therapy.
    Morais J.
    Cerebrovasc Dis; 2002; 13 Suppl 1():17-21. PubMed ID: 11803183
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
    Greenhalgh J, Bagust A, Boland A, Martin Saborido C, Oyee J, Blundell M, Dundar Y, Dickson R, Proudlove C, Fisher M.
    Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
    Jamieson DG, Parekh A, Ezekowitz MD.
    J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evolving perspectives on clopidogrel in the treatment of ischemic stroke.
    Gorelick P, Sechenova O, Hennekens CH.
    J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):245-8. PubMed ID: 17220470
    [Abstract] [Full Text] [Related]

  • 17. Antiplatelet therapy in populations at high risk of atherothrombosis.
    Faxon DP, Nesto RW.
    J Natl Med Assoc; 2006 May; 98(5):711-21. PubMed ID: 16749646
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
    Hoh BL, Gong Y, McDonough CW, Waters MF, Royster AJ, Sheehan TO, Burkley B, Langaee TY, Mocco J, Zuckerman SL, Mummareddy N, Stephens ML, Ingram C, Shaffer CM, Denny JC, Brilliant MH, Kitchner TE, Linneman JG, Roden DM, Johnson JA.
    J Neurosurg; 2016 Jun; 124(6):1746-51. PubMed ID: 26587656
    [Abstract] [Full Text] [Related]

  • 20. Future perspectives for optimizing oral antiplatelet therapy.
    Easton JD.
    Cerebrovasc Dis; 2001 Jun; 11 Suppl 2():23-8. PubMed ID: 11316919
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.